image credit: Vecteezy

Vertex islet cell therapy gets type 1 diabetics off insulin

June 24, 2024

The new data from Vertex’s phase 1/2 trial of VX-880, presented at the American Diabetes Association (ADA) annual congress in Florida, suggest that the therapy can restore the physiological activity of the insulin-producing islet cells of the pancreas and restore glucose control.

The study enrolled 17 people with type 1 diabetes and impaired hypoglycaemia awareness, meaning they find it hard to spot the telltale signs of declining blood sugar levels and are at increased risk of severe hypoglycaemic events (SHEs) that can cause confusion, coma, seizures, cardiovascular events, and even death.

Read More on Pharmaphorum